News
-
-
-
-
-
PRESS RELEASE
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
Defence Therapeutics Inc. receives Health Canada's No Objection Letter for Phase I trial of ACCUM-002 as anti-cancer drug in melanoma patients. The study aims to assess safety, tolerability, and efficacy of the drug -
PRESS RELEASE
COFICERT: COFICERT and Renoir Consulting sign a strategic partnership for the deployment of the certification standard: ESG 1000
COFICERT and Renoir Consulting announce strategic partnership for the deployment of ESG 1000 certification standard, enhancing Sustainability & CSR practices globally -
PRESS RELEASE
COFICERT: COFICERT and Renoir Consulting signent un partenariat stratégique pour le déploiement de la norme certifiable ESG 1000
COFICERT et Renoir Consulting signent un partenariat stratégique pour le déploiement de la norme certifiable ESG 1000. Le partenariat vise à accompagner les entreprises dans leur transformation vers des pratiques durables et garantir le respect des contraintes réglementaires -
PRESS RELEASE
Quadpack makes EUR 50,000 cash injection into liquidity contract with Invest Securities
Quadpack Industries announces a €50,000 cash contribution to its liquidity contract with Invest Securities to balance cash and shares on Euronext Growth. The move aims to ensure share price stability and compliance with market regulations -
PRESS RELEASE
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment -
PRESS RELEASE
AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19
AB Science annonce des résultats positifs de son étude de phase 2 évaluant le masitinib dans la COVID-19. Les analyses montrent un potentiel traitement prometteur pour les patients hospitalisés
